A targeted approach to treating glioma
(Massachusetts Institute of Technology) Researchers from MIT, Brigham and Women's Hospital, and Massachusetts General Hospital have developed a new way to treat low-grade glioma. They devised a test that can rapidly check for the IDH mutation during brain surgery, and if the mutation is present, they can implant microparticles that gradually release an IDH-targeted drug over several days or weeks.
Authors: Hozumi K, Fukuoka H, Odake Y, Takeuchi T, Uehara T, Sato T, Inoshita N, Yoshida K, Matsumoto R, Bando H, Hirota Y, Iguchi G, Taniguchi M, Otsuki N, Nishigori C, Kosaki K, Hasegawa T, Ogawa W, Takahashi Y Abstract Although acromegaly has been reported in patients with Neurofibromatosis type 1 (NF1), these cases have not been associated with growth hormone (GH)-producing somatotroph adenoma, but with optic pathway glioma. A 68 year-old Japanese woman, who had been clinically diagnosed with NF1, was referred to our hospital due to a thyroid tumor and hypercalcemia. Acromegaly was suspected due to her facial f...
Molecular imaging firm Blue Earth Diagnostics is touting 16 presentations involving...Read more on AuntMinnie.comRelated Reading: Blue Earth touts presentations at AUA 2019 Blue Earth study reports Axumin can aid glioma diagnosis Blue Earth promotes results for PET/CT agent Blue Earth expands PSMA-PET/CT imaging portfolio Blue Earth touts addition of Axumin to NCCN guidelines
A team at Tampere University, Finland has developed a technique using surgical smoke that allows neurosurgeons to ID cancerous tissue during surgery. A new method developed by researchers at Tampere University in Finland helps analyze surgical smoke to distinguish between malignant tissue and health tissue. The researcherâs work was recently published in the Journal of Neurosurgery. The technology is based on differential mobility spectrometry, wherein flue gas ions are fed into an electric field. The distribution of ions in the electric field is tissue-specific, and the tissue can be identified on the ba...
Chow Peter D. Chang Radiographic assessment with magnetic resonance imaging (MRI) is widely used to characterize gliomas, which represent 80% of all primary malignant brain tumors. Unfortunately, glioma biology is marked by heterogeneous angiogenesis, cellular proliferation, cellular invasion, and apoptosis. This translates into varying degrees of enhancement, edema, and necrosis, making reliable imaging assessment challenging. Deep learning, a subset of machine learning artificial intelligence, has gained traction as a method, which has seen effective employment in solving image-based problems, including those in me...
CONCLUSIONS: The authors' results show that surgical smoke from various brain tumors has distinct DMS profiles and the DMS analyzer connected to a special sampling system can differentiate between tumorous and nontumorous tissue and also between different tumor types ex vivo. PMID: 31200382 [PubMed - as supplied by publisher]
Conclusion: Our work identified a novel pharmacologic strategy to accelerate the clinical application of the non-invasive NSCs-based therapeutic platform to tackle aggressive brain tumors.
Conclusions: This study suggests that p62 is an effector for HMGB1-induced EMT, and may represent a novel therapeutic target in GBM.
Conclusion: The results clearly indicated that a combination of 68Ga-DOTA-labeled EPI@CPP-gVLPs and CED can serve as a flexible and powerful synergistic treatment in brain tumors without evidence of systemic toxicity.
Conclusions: Our findings indicate that the oncogenic MSH6-CXCR4-TGFB1 feedback loop is a novel therapeutic target for GBM and that PTT is associated with the inhibition of the MSH6-CXCR4-TGFB1 loop.